Clinical Trial Update: A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing AK104 given subcutaneously with XELOX vs AK104 given intravenously with XELOX in unresectable locally advanced or metastatic ga…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Akeso | Conditions: Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: NOT_YET_RECRUITING